The whole-body deletion or pharmacological inhibition of TMEM176B in murine cancer models decreased tumor growth through enhanced anti-tumor T cell immunity and improved the response to immune checkpoint inhibitors [4,10]. Here, TMEM176B is linked to neoplasm.